Zu-Jiang Yu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/855575/publications.pdf

Version: 2024-02-01

30 papers	687 citations	759233 12 h-index	580821 25 g-index
32 all docs	32 docs citations	32 times ranked	1700 citing authors

#	Article	IF	CITATIONS
1	Tenofovir Alafenamide for Pregnant Chinese Women With Active Chronic Hepatitis B: A Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2826-2837.e9.	4.4	6
2	Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study. Clinical Infectious Diseases, 2021, 73, e3324-e3332.	5.8	29
3	Overexpressed Tumor Suppressor Exosomal miR-15a-5p in Cancer Cells Inhibits PD1 Expression in CD8+T Cells and Suppresses the Hepatocellular Carcinoma Progression. Frontiers in Oncology, 2021, 11, 622263.	2.8	18
4	Tenofovir disoproxil fumarate in Chinese chronic hepatitis B patients: Results of a multicenter, double-blind, double-dummy, clinical trial at 96 weeks. World Journal of Clinical Cases, 2021, 9, 4690-4699.	0.8	0
5	Irreversible electroporation plus chemotherapy versus chemotherapy alone as treatments for patients with locally advanced pancreatic cancer. Hepatobiliary and Pancreatic Diseases International, 2021, 21, 69-69.	1.3	О
6	Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment. Hepatobiliary and Pancreatic Diseases International, 2021, 20, 416-425.	1.3	11
7	Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study. BMC Infectious Diseases, 2021, 21, 818.	2.9	10
8	p65/miRâ€23a/CCL22 axis regulated regulatory T cells recruitment in hepatitis B virus positive hepatocellular carcinoma. Cancer Medicine, 2020, 9, 711-723.	2.8	12
9	Reply to Rabelo-da-Ponte et al. Journal of Infectious Diseases, 2020, 222, 1578-1578.	4.0	О
10	Human microbiome is a diagnostic biomarker in hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 109-115.	1.3	25
11	Clinical course and treatment efficacy of COVIDâ€19 near Hubei Province, China: A multicentre, retrospective study. Transboundary and Emerging Diseases, 2020, 67, 2971-2982.	3.0	26
12	Short-term Peginterferon-Induced High Functional Cure Rate in Inactive Chronic Hepatitis B Virus Carriers With Low Surface Antigen Levels. Open Forum Infectious Diseases, 2020, 7, ofaa208.	0.9	13
13	Massive abdominal hemorrhage after radiofrequency ablation of recurrent hepatocellular carcinoma with successful hemostasis achieved through transarterial embolization: a case report. Journal of International Medical Research, 2020, 48, 030006051989801.	1.0	1
14	Fecal microbiota transplantation has therapeutic effects on chronic hepatits B patients via altering composition of gut microbiota. Hepatobiliary and Pancreatic Diseases International, 2020, 19, 486-487.	1.3	4
15	Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. Journal of Infectious Diseases, 2020, 222, 38-43.	4.0	279
16	Recent progress in pulsed electric field ablation for liver cancer. World Journal of Gastroenterology, 2020, 26, 3421-3431.	3.3	14
17	ILâ€17Aâ€mediated ERK1/2/p65 signaling pathway is associated with cell apoptosis after nonâ€alcoholic steatohepatitis. IUBMB Life, 2019, 71, 302-309.	3.4	7
18	Management of individuals with chronic hepatitis B virus infection and persistent normal or mildly elevated aminotransferase levels. Journal of Cellular Biochemistry, 2019, 120, 6632-6641.	2.6	7

#	Article	IF	CITATIONS
19	On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B. World Journal of Gastroenterology, 2019, 25, 4764-4778.	3.3	14
20	MiRâ€19a Affects Hepatocyte Autophagy via Regulating lncRNA NBR2 and AMPK/PPARα in Dâ€GalN/Lipopolysaccharideâ€6timulated Hepatocytes. Journal of Cellular Biochemistry, 2018, 119, 358-365.	2.6	21
21	The development of hepatocarcinoma after long-term antivirus treatment of Chinese patients with chronic hepatitis B virus infection: Incidence, long-term outcomes and predictive factors. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 311-318.	1.5	17
22	Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study. Journal of Hepatology, 2017, 66, 1123-1129.	3.7	44
23	Knockdown of HIPK2 attenuates the pro-fibrogenic response of hepatic stellate cells induced by TGF- \hat{l}^21 . Biomedicine and Pharmacotherapy, 2017, 85, 575-581.	5.6	12
24	AMPK activation ameliorates D-GalN/LPS-induced acute liver failure by upregulating Foxo3A to induce autophagy. Experimental Cell Research, 2017, 358, 335-342.	2.6	18
25	Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?. Journal of Hepatology, 2016, 65, 1068-1069.	3.7	33
26	Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study. Gut and Liver, 2016, 10, 955-961.	2.9	6
27	Regulation of the oncogenic function of distal-less 4 by microRNA-122 in hepatocellular carcinoma. Molecular Medicine Reports, 2015, 12, 1375-1380.	2.4	11
28	Prevalence of Hepatitis C Virus and Hepatitis B Virus Infections in Patients Infected with HIV Through Blood Donation or Transfusion in China. AIDS Research and Human Retroviruses, 2015, 31, 1203-1203.	1.1	2
29	Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 336-341.	1.0	7
30	Expression profile of altered long non-coding RNAs in patients with HBV-associated hepatocellular carcinoma. Journal of Huazhong University of Science and Technology [Medical Sciences], 2013, 33, 96-101.	1.0	36